Transcatheter Strategy for Severe Mitral Regurgitation Requiring Percutaneous Ventricular Assist Device Support

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Severe mitral regurgitation and advanced chronic heart failure requiring Impella support (n=33). Intervention: Transcatheter strategy (M-TEER using MitraClip during Impella support) vs. Conservative strategy (Impella support and intensive medical therapy without mitral valve intervention). Primary outcome: In-hospital death (HR 0.13, 95% CI 0.03-0.52, p=0.004).

Tsuyoshi Isawa; Yusuke Toki; Masataka Taguri; Norio Tada; Shigeru Toyoda; on behalf of the J-PVAD Investigators

doi:10.1253/circrep.cr-26-0155

August 30, 2026Circulation ReportsOpen Access

Transcatheter Strategy for Severe Mitral Regurgitation Requiring Percutaneous Ventricular Assist Device Support

View Full Paper

Ask AI

Bookmark

Share

Figures

Why the study?

Data on transcatheter strategies in patients with severe mitral regurgitation and advanced chronic heart failure requiring Impella support remain limited.

Does a transcatheter strategy (M-TEER) reduce in-hospital death in patients with severe mitral regurgitation and advanced chronic heart failure requiring Impella support compared to a conservative strategy?

Key Points

To evaluate the clinical outcomes of a transcatheter repair strategy compared with conservative management in patients with severe mitral regurgitation and advanced chronic heart failure requiring Impella support.
A retrospective cohort study was conducted using a nationwide Japanese registry of patients with severe mitral regurgitation and advanced chronic heart failure requiring Impella support between February 2020 and December 2023 (N=33).
Patients received either a transcatheter strategy with mitral transcatheter edge-to-edge repair using the MitraClip system (n=17) or a conservative strategy of Impella support and medical therapy without intervention (n=16).
The primary outcome of in-hospital death was evaluated using an unadjusted and an overlap-weighted Cox proportional hazards model adjusted for baseline covariates.
In-hospital mortality was 29% (5/17) in the transcatheter group compared with 69% (11/16) in the conservative strategy group.
Unadjusted analysis associated the transcatheter strategy with a reduced risk of in-hospital death (HR: 0.18, 95% CI: 0.05–0.58, P=0.004).
In the overlap-weighted Cox model, the transcatheter strategy remained associated with lower in-hospital mortality (hazard ratio, 0.13; 95% confidence interval, 0.03–0.52; P=0.004).

Study Design

Type

Cohort (n=33)

Multicenter

Yes

Structured PICO

Does a transcatheter strategy (M-TEER) reduce in-hospital death in patients with severe mitral regurgitation and advanced chronic heart failure requiring Impella support compared to a conservative strategy?

P

Population

33 patients with severe mitral regurgitation and advanced chronic heart failure requiring Impella support for hemodynamic stabilization, evaluated for in-hospital outcomes.

E

Exposure

Transcatheter strategy defined as mitral transcatheter edge-to-edge repair (M-TEER) using the MitraClip system during Impella support.

C

Comparator

Conservative strategy comprising Impella support and intensive medical therapy without mitral valve intervention.

O

Outcome

In-hospital deathhard clinical

Main Result

Hazard Ratio: 0.13 (95% CI 0.03–0.52)

Absolute Event Rate: 29% vs 69%

p-value: p=0.004

Limitations

Small sample size restricts generalizability
Retrospective observational design

Implication

In patients with advanced heart failure and severe mitral regurgitation requiring Impella support, performing M-TEER was associated with a significantly lower in-hospital mortality rate compared to medical therapy alone.

Abstract

Background: Data on transcatheter strategies in patients with severe mitral regurgitation (MR) and advanced chronic heart failure requiring Impella support remain limited. Methods and Results: We retrospectively analyzed 33 patients with severe MR and advanced chronic heart failure requiring Impella support, treated with a transcatheter strategy (n=17) or a conservative strategy (n=16). In an overlapweighted Cox model, the transcatheter strategy was associated with a lower in-hospital mortality rate (hazard ratio, 0.13; 95% confidence interval, 0.03-0.52; P=0.004). Conclusions: A transcatheter strategy had survival benefit for this high-risk population.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Isawa et al. (2026) conducted a cohort in Severe mitral regurgitation and advanced chronic heart failure requiring Impella support (n=33). Transcatheter strategy (M-TEER using MitraClip during Impella support) vs. Conservative strategy (Impella support and intensive medical therapy without mitral valve intervention) was evaluated on In-hospital death (HR 0.13, 95% CI 0.03-0.52, p=0.004).

synapsesocial.com/papers/6a969a7f535111e2d4ce8caa https://doi.org/10.1253/circrep.cr-26-0155

View Full Paper

Ask AI

Bookmark

Share

Transcatheter Strategy for Severe Mitral Regurgitation Requiring Percutaneous Ventricular Assist Device Support

Figures

Key Points

Study Design

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Cite This Study

Transcatheter Strategy for Severe Mitral Regurgitation Requiring Percutaneous Ventricular Assist Device Support

Figures

Key Points

Study Design

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading